MULTISYSTEM IMPACT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN CLINICAL PRACTICE

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is closely linked to obesity, type 2 diabetes, dyslipidemia, and arterial hypertension. The 2023 change in nomenclature placed cardiometabolic dysfunction at the center of the diagnosis and reinforced the understanding of the condition as a systemic disorder, whose consequences extend well beyond the liver. This review aimed to analyze the multisystem impact of MASLD and to discuss its implications for the daily practice of the clinician, including risk stratification, follow-up, and treatment. This is a narrative literature review, guided by a structured question based on the PICo strategy and directed at studies on the hepatic and extrahepatic outcomes of adults with MASLD. The evidence shows that the disease is associated with a higher risk of fatal and nonfatal cardiovascular events, heart failure, incident type 2 diabetes, chronic kidney disease, and extrahepatic cancers, with risk increasing according to the severity of liver disease, especially the stage of fibrosis. Cardiovascular disease and extrahepatic cancers account for a large share of the excess mortality, while fibrosis remains the main determinant of liver outcomes. Noninvasive assessment of fibrosis, starting with FIB-4 and followed by elastography when indicated, allows the identification of patients at higher risk in primary care. Lifestyle intervention remains the basis of treatment, and recent trials with resmetirom and semaglutide have expanded the pharmacological options for steatohepatitis with significant fibrosis. It is concluded that MASLD should be approached as a multisystem cardiometabolic disease, requiring integrated management of liver, cardiovascular, renal, and metabolic risk by the clinician.

Authors

Publication Details

Journal
Artefactum
Published
2026-11-19
DOI
https://doi.org/10.23900/artefactum.v25i14.141
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

MULTISYSTEM IMPACT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN CLINICAL PRACTICE

Dianah Dantas Pulvirenti, Maria Júlia Daniel Peixoto, Mirella Cristina Mazuqueli Marques, Luciléia Mazuqueli Marques et al.
Artefactum
Liver Disease Diagnosis and Treatment
article

MULTISYSTEM IMPACT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE IN CLINICAL PRACTICE

Dianah Dantas Pulvirenti, Maria Júlia Daniel Peixoto, Mirella Cristina Mazuqueli Marques, Luciléia Mazuqueli Marques, Rodolfo de Oliveira Medeiros, ANA CAROLINA FONTANA BOLSONI, Bruna Gonçalves Manzoni, Guilherme Augusto Ferrari Pavoni, Luiz Carlos Borsanelli Júnior, Flávio Renan Ramiro, Guilherme Almeida dos Reis Santos, Beatriz Camilly Fernandes, Edna Pereira da Silva
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and is closely linked to obesity, type 2 diabetes, dyslipidemia, and arterial hypertension. The 2023 change in nomenclature placed cardiometabolic dysfunction at the center of the diagnosis and reinforced the understanding of the condition as a systemic disorder, whose consequences extend well beyond the liver. This review aimed to analyze the multisystem impact of MASLD and to discuss its implications for the daily practice of the clinician, including risk stratification, follow-up, and treatment. This is a narrative literature review, guided by a structured question based on the PICo strategy and directed at studies on the hepatic and extrahepatic outcomes of adults with MASLD. The evidence shows that the disease is associated with a higher risk of fatal and nonfatal cardiovascular events, heart failure, incident type 2 diabetes, chronic kidney disease, and extrahepatic cancers, with risk increasing according to the severity of liver disease, especially the stage of fibrosis. Cardiovascular disease and extrahepatic cancers account for a large share of the excess mortality, while fibrosis remains the main determinant of liver outcomes. Noninvasive assessment of fibrosis, starting with FIB-4 and followed by elastography when indicated, allows the identification of patients at higher risk in primary care. Lifestyle intervention remains the basis of treatment, and recent trials with resmetirom and semaglutide have expanded the pharmacological options for steatohepatitis with significant fibrosis. It is concluded that MASLD should be approached as a multisystem cardiometabolic disease, requiring integrated management of liver, cardiovascular, renal, and metabolic risk by the clinician.

ArtefactumVol. 25(14)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon